Lazard announced today that Dr. Geoffrey Porges has joined the firm as Managing Director in the Healthcare Advisory Group, advising on transactions across diversified biopharmaceuticals.

“We are thrilled to welcome Geoffrey to Lazard,” said David Gluckman, Vice Chairman of Investment Banking and Global Head of Healthcare. “His deep understanding of the biopharmaceutical industry's strategic and financial landscape, coupled with his ability to help companies translate scientific innovation into actionable business strategies, will empower our clients to strengthen their competitive positions, capitalize on growth opportunities, and build resilient companies in a challenging geopolitical and macroeconomic environment.”

Dr. Porges brings more than 30 years of experience in advisory, executive, and investment roles in the biopharmaceutical industry. Most recently, he served as EVP and Chief Financial Officer at Schrödinger, where he oversaw financial operations, investor relations, corporate communications, strategic planning and business development. Previously, he was the head of biopharma equity research at SVB Leerink and senior biotechnology equity research analyst Sanford C. Bernstein, consistently earning recognition as one of Wall Street’s top analysts. Earlier, Dr. Porges held senior roles at BTG PLC and Merck & Co.

“Lazard’s deep expertise in healthcare and biopharma makes it an ideal platform to help clients tackle key strategic and financial challenges,” said Dr. Porges. “I’m excited to join this world-class team and begin working with clients as they make critical decisions in a dynamic environment.”

Dr. Porges earned his medical degree from the University of Sydney and an MBA from Harvard Business School, where he was a Baker Scholar.

About Lazard

Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Lazard is listed on the New York Stock Exchange as Lazard, Inc. under the ticker LAZ. For more information, please visit Lazard.com and follow Lazard on LinkedIn.

LAZ-CPE

View source version on businesswire.com: https://www.businesswire.com/news/home/20250918506743/en/

“Lazard’s deep expertise in healthcare and biopharma makes it an ideal platform to help clients tackle key strategic and financial challenges,” said Dr. Porges.